{"id":"NCT03690206","sponsor":"Zealand Pharma","briefTitle":"Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)","officialTitle":"A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Glepaglutide in Patients With Short Bowel Syndrome (SBS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-04","primaryCompletion":"2022-07-26","completion":"2022-07-26","firstPosted":"2018-10-01","resultsPosted":"2024-10-21","lastUpdate":"2025-07-17"},"enrollment":106,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Short Bowel Syndrome"],"interventions":[{"type":"DRUG","name":"glepaglutide","otherNames":["ZP1848"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Glepaglutide SC injections twice weekly","type":"EXPERIMENTAL"},{"label":"Glepaglutide SC injections once weekly and placebo once weekly","type":"EXPERIMENTAL"},{"label":"Placebo SC injections twice weekly","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of the trial is to confirm the efficacy of glepaglutide in reducing parenteral support volume in patients with short bowel syndrome.\n\nGlepaglutide is the International Nonproprietary Name and USAN for ZP1848.","primaryOutcome":{"measure":"Change in Weekly Parenteral Support (PS) Volume","timeFrame":"24 weeks","effectByArm":[{"arm":"Glepaglutide SC Injections Twice Weekly","deltaMin":-5.13,"sd":null},{"arm":"Glepaglutide SC Injections Once Weekly and Placebo Once Weekly","deltaMin":-3.76,"sd":null},{"arm":"Placebo SC Injections Twice Weekly","deltaMin":-2.85,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0039"},{"comp":"OG001 vs OG002","p":"0.2700"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":19},"locations":{"siteCount":29,"countries":["United States","Belgium","Canada","Denmark","France","Germany","Netherlands","Poland","United Kingdom"]},"refs":{"pmids":["39708985"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":35},"commonTop":["Injection site reaction","Abdominal pain","Injection site erythema","Nausea","Headache"]}}